Gilead Sciences (FRA:GIS) Short-Term Debt: €1,136 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:GIS Gilead Sciences Inc FRA:GIS
75 GF Score
Price €113.24
GF Value €82.49
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Gilead Sciences Short-Term Debt?

Gilead Sciences FRA:GIS -3.67% 75 Short-Term Debt is €1,136 Mil as of Mar. 2026. GuruFocus rates FRA:GIS with a GF Score™ of 75/100 and a GF Value™ of €82.49 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Gilead Sciences's Short-Term Debt for the quarter that ended in Mar. 2026 was €1,136 Mil.

Gilead Sciences's quarterly Short-Term Debt increased from Sep. 2025 (€2,391 Mil) to Dec. 2025 (€2,397 Mil) but then declined from Dec. 2025 (€2,397 Mil) to Mar. 2026 (€1,136 Mil).

Gilead Sciences's annual Short-Term Debt increased from Dec. 2023 (€1,649 Mil) to Dec. 2024 (€1,733 Mil) and increased from Dec. 2024 (€1,733 Mil) to Dec. 2025 (€2,397 Mil).

Gilead Sciences Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Gilead Sciences Short-Term Debt Related Terms

Gilead Sciences Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Gilead Sciences's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences Short-Term Debt Chart

Gilead Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,341.66 2,145.71 1,648.77 1,733.33 2,397.18

Gilead Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,595.55 2,432.80 2,390.71 2,397.18 1,135.75
FRA:GIS
75GF Score
Gilead Sciences Inc FRA:GIS
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €1,136 Mil mean?
Gilead Sciences (FRA:GIS) has a Short-Term Debt of €1,136 Mil as of Mar. 2026.
Is Gilead Sciences' Short-Term Debt too high?
Gilead Sciences' current Short-Term Debt is €1,136 Mil. Overall, Gilead Sciences has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Short-Term Debt compare to PFE and BMY?
Gilead Sciences' Short-Term Debt of €1,136 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Gilead Sciences's current Short-Term Debt is €1,136 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €82.49, compared to a current price of €113.24 — trading 37.3% above its estimated fair value. The current Short-Term Debt is €1,136 Mil. Gilead Sciences' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current Short-Term Debt is €1,136 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gilead Sciences (FRA:GIS) Overvalued in 2026?

Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued. The current stock price of €113.24 is trading 37.3% above its estimated GF Value™ of €82.49. GuruFocus considers Gilead Sciences to be Significantly Overvalued.

Key valuation signals for FRA:GIS:

  • Short-Term Debt: €1,136 Mil
  • GF Value™: €82.49 vs. price of €113.24 (37.3% above fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gilead Sciences Business Description

Address 333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
75GF Score

Get the complete analysis for FRA:GIS

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€113.24
Price
€82.49
GF Value